Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.
Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS.
Jabbour EJ, et al.
Cancer. 2015 Mar 15;121(6):876-82. doi: 10.1002/cncr.29145. Epub 2014 Nov 19.
Cancer. 2015.
PMID: 25410759
Free PMC article.